4d Pharma PLC Directorate Change (5492N)
21 Mayo 2020 - 01:00AM
UK Regulatory
TIDMDDDD
RNS Number : 5492N
4d Pharma PLC
21 May 2020
4D pharma plc
(the "Company" or "4D")
Directorate Change
4D announces the resignation from its board of Thomas Engelen,
Non-executive Director, for personal reasons with effect from 20
May 2020.
Duncan Peyton, CEO, commented: "On behalf of the Board, I would
like to express our gratitude to Thomas for the contribution made
during his tenure, which stretches back to the flotation of the
Company in 2014. We wish him the very best for the future."
The 4D Board has four continuing non-executive directors, three
of which are deemed to be independent, including the Chairperson,
Professor Dr. med. Axel Glasmacher. As such, the Board will
comprise a total of six directors, with the independent Chairperson
holding a casting vote.
About 4D
Founded in February 2014, 4D pharma is a world leader in the
development of Live Biotherapeutics, a novel and emerging class of
drugs, defined by the FDA as biological products that contain a
live organism, such as a bacterium, that is applicable to the
prevention, treatment or cure of a disease. 4D has developed a
proprietary platform, MicroRx(R), that rationally identifies Live
Biotherapeutics based on a deep understanding of function and
mechanism.
4D's Live Biotherapeutic Products are orally delivered single
strains of bacteria that are naturally found in the healthy human
gut. The Company has five clinical studies in progress, namely a
Phase II clinical study of BLAUTIX(R) in Irritable Bowel Syndrome
(IBS), a Phase I/II study of MRx0518 in combination with
KEYTRUDA(R) (pembrolizumab) in solid tumours, a Phase I study of
MRx0518 in a neoadjuvant setting for patients with solid tumours, a
Phase I study of MRx0518 in patients with pancreatic cancer and a
Phase I/II study of MRx-4DP0004 in asthma. Preclinical-stage
programmes include candidates for CNS disease such as Parkinson's
disease and other neurodegenerative conditions. The Company has a
research collaboration with MSD, a tradename of Merck & Co.,
Inc., Kenilworth, NJ, USA, to discover and develop Live
Biotherapeutics for vaccines.
For more information, refer to https://www.4dpharmaplc.com .
Contact Information:
4D
Duncan Peyton, Chief Executive Officer + 44 (0)113 895 0130
Investor Relations ir@4dpharmaplc.com
N+1 Singer - Nominated Adviser and Joint Broker +44 (0) 20 7496
3000
Aubrey Powell / Justin McKeegan / Alex Bond / Iqra Amin
(Corporate Finance)
Tom Salvesen (Corporate Broking)
Bryan Garnier & Co. Limited - Joint Broker +44 (0)20 7332
2500
Dominic Wilson / Phil Walker
Image Box PR
Neil Hunter / Michelle Boxall
Tel +44 (0)20 8943 4685
neil@ibcomms.agency / michelle@ibcomms.agency
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
BOAURUKRRNUVUAR
(END) Dow Jones Newswires
May 21, 2020 02:00 ET (06:00 GMT)
4d Pharma (LSE:DDDD)
Gráfica de Acción Histórica
De Feb 2024 a Mar 2024
4d Pharma (LSE:DDDD)
Gráfica de Acción Histórica
De Mar 2023 a Mar 2024